GlassScriptPhysician profile
Jeri Wells Lloyd
NPI 1366053431
$1,105.21
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.88 · 2022: $96.71 · 2023: $449 · 2024: $154 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.13 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.00 | 2023-2024 | Iclusig |
| Merck Sharp & Dohme LLC | $82.02 | 2021-2025 | Keytruda |
| Invivyd INC | $70.02 | 2025 | Pemgarda |
| Argenx US, INC. | $69.62 | 2024-2025 | Vyvgart Hytrulo |
| Daiichi Sankyo INC. | $67.37 | 2023-2024 | Injectafer, Enhertu |
| Abbvie INC. | $60.13 | 2023-2024 | |
| Genentech USA, INC. | $51.57 | 2024-2025 | Ocrevus Zunovo, Phesgo |
| Incyte Corporation | $49.60 | 2023 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $47.28 | 2025 | Lynozyfic |
| Amgen INC. | $42.25 | 2022-2023 | Kyprolis, Blincyto |
| Legend Biotech USA INC. | $38.15 | 2025 | Carvykti |
| Stemline Therapeutics INC. | $37.10 | 2024-2025 | Elzonris |
| Urogen Pharma, INC. | $33.55 | 2025 | |
| Celgene Corporation | $32.08 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $24.58 | 2023 | Darzalex |
| Coherus Oncology, INC. | $23.21 | 2024 | |
| Servier Pharmaceuticals LLC | $22.18 | 2023 | |
| Sanofi Pasteur INC. | $19.90 | 2022 | |
| Immunogen, INC. | $19.36 | 2023 | Elahere |
| Adc Therapeutics America, INC. | $17.81 | 2023 | |
| Genzyme Corporation | $17.77 | 2023 | |
| Janssen Biotech, INC. | $16.37 | 2024 | Talvey |
| Organon LLC | $15.72 | 2023 | Ontruzant, Renflexis |
| Alexion Pharmaceuticals, INC. | $15.44 | 2023 | Soliris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeri Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.